Tocilizumab for Patients With Cancer and COVID-19 Disease

NCT04370834 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

NIH

Sponsor class

Stopped Other - Randomized data no longer support continuation

Conditions

Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm
Pneumonia
Pneumonitis
Severe Acute Respiratory Distress Syndrome
Symptomatic COVID-19 Infection Laboratory-Confirmed

Interventions

BIOLOGICAL: Tocilizumab

Sponsor

National Cancer Institute (NCI)